Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
← catalyst calendarNCT07792408 · readout in 194 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
148estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-28 | estimated | When the study began enrolling |
| Primary completion | 2027-03-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
- Drug: VX-407
- Drug: LNG/EE
- Drug: NGM/EE
- Drug: NET/EE
- Drug: DRSP/EE
Primary outcomes
what the primary-completion date above is the date OFPart A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 7 and Day 21 up to Day 27
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 9 and Day 23 up to Day 31
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 5 and Day 19 up to Day 23
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 7 and Day 21 up to Day 27
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 7 and Day 21 up to Day 27
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 9 and Day 23 up to Day 31
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 5 and Day 19 up to Day 23
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407
measured From Day 1 up to Day 7 and Day 21 up to Day 27
Related
VRTX · their whole pipeline · Who in Congress owns VRTX? · Executive-branch trades in VRTX
VRTX's other studiesmost recently updated first
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease Phase 2/3 · Recruiting
- A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) Phase 1/2 · Active, not recruiting
- Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities Phase 2 · Completed
- Evaluation of Pain Treatment After Total Knee Arthroplasty Phase 4 · Recruiting
- Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants Phase 1 · Completed
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed